Stockscreener 앱 받기
2.20
1.35%
-0.03
전일 마감가:
$2.23
열려 있는:
$2.19
하루 거래량:
117.27K
Relative Volume:
0.09
시가총액:
$20.44M
수익:
-
순이익/손실:
$-45.57M
주가수익비율:
-0.3492
EPS:
-6.3
순현금흐름:
$-38.56M
1주 성능:
-1.35%
1개월 성능:
-14.73%
6개월 성능:
+6.80%
1년 성능:
-18.82%
1일 변동 폭
$2.13
$2.2575
1주일 범위
$2.1201
$2.3929
52주 변동 폭
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
SABS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
2.20 | 20.34M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB Biotherapeutics Inc. Equity Warrant stock retracement – recovery analysisShort Term Momentum Based Trading Strategy - Newser
Applying Elliott Wave Theory to SAB Biotherapeutics Inc. Equity WarrantLong-Term Signal Tracking and Profit Summary - Newser
SAB Biotherapeutics Inc. stock volume spike explainedMinimal Risk Growth Investment Opportunity Analysis - Newser
Price momentum metrics for SAB Biotherapeutics Inc. explainedReal Stock Picks With Setup Verification - Newser
Will SAB Biotherapeutics Inc. stock benefit from interest rate changesFree Trade Timing Strategy With Technical Data - Newser
Analyzing SAB Biotherapeutics Inc. with multi timeframe chartsFree Breakout Momentum Picks With Protection - Newser
SAB Biotherapeutics Inc. stock chart pattern explainedAI Trend Detection for Entry Timing - Newser
Risk adjusted return profile for SAB Biotherapeutics Inc. Equity Warrant analyzedSecure Asset Flow and Trend Pattern Analysis - Newser
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Technical analysis overview for SAB Biotherapeutics Inc. stockDaily Pick Forecast with Entry Zones - Newser
Measuring SAB Biotherapeutics Inc.’s beta against major indicesShort-Term Bounce Forecast for Oversold Stocks - Newser
Should you hold or exit SAB Biotherapeutics Inc. Equity Warrant nowLong-Term Investment Strategy Summary Guide - Newser
What the charts say about SAB Biotherapeutics Inc. todayValue Holding Return Summary With Outlook - Newser
How hedge fund analytics apply to SAB Biotherapeutics Inc. Equity Warrant stockPredictable Income Summary for Long-Term Trades - Newser
Is SAB Biotherapeutics Inc. Equity Warrant Stock a Smart Buy in 2025 Investment Analysis InsideMulti-Bagger Detection with Trend Tools - Newser
Top chart patterns to watch in SAB Biotherapeutics Inc.Daily Market Momentum Summary and Strategy - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionLow Risk Strategy with Smart Entry Zones - Newser
Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20 - Investing.com Canada
SAB Biotherapeutics 2024 Q4 Earnings Significant Loss Widening Despite Revenue Decline - AInvest
What high frequency data says about SAB Biotherapeutics Inc. Equity WarrantDownside Risk Evaluation and Stock Analysis - Newser
SAB Biotherapeutics Reports Increased Losses Amid Funding Boost - TipRanks
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics Expected to Beat Earnings Estimates Ahead of Q2 Release. - AInvest
SAB Bio reports strong cash position with completed financing extending operational runway - MarketScreener
SAB BIO raises $175 mln, extends runway to mid-2028, initiates Phase 2b study in Q3 2025 - AInvest
SAB Biotherapeutics, Inc. SEC 10-Q Report - TradingView
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates - GlobeNewswire
SAB Bio Lands Massive $175M Investment from Sanofi for Revolutionary Type 1 Diabetes Treatment - Stock Titan
SAB Biotherapeutics Inc expected to post a loss of 80 cents a shareEarnings Preview - TradingView
SAB Biotherapeutics Inc. Could See a Relief Rally From SupportRisk Controlled Short Term Trade Plans Published - beatles.ru
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. stockAchieve rapid financial growth with smart picks - Jammu Links News
What are the technical indicators suggesting about SAB Biotherapeutics Inc.Unmatched profit growth - Jammu Links News
Live Scanner Shows Breakout on SAB Biotherapeutics Inc. Equity WarrantWatchlist for Low Risk High Return Stocks Updated - metal.it
What institutional investors are buying SAB Biotherapeutics Inc. Equity Warrant stockUnlock powerful trading strategies for gains - Jammu Links News
Is SAB Biotherapeutics Inc. stock overvalued or undervaluedSkyrocketing returns - Jammu Links News
SAB Biotherapeutics Inc. Stock Analysis and ForecastFree Expert Stock Watchlist - Jammu Links News
What institutional investors are buying SAB Biotherapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
Is SAB Biotherapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - Jammu Links News
When is SAB Biotherapeutics Inc. stock expected to show significant growthBoost your returns with professional guidance - Jammu Links News
What are analysts’ price targets for SAB Biotherapeutics Inc. in the next 12 monthsBuild a portfolio with strong long-term growth - Jammu Links News
Published on: 2025-08-03 17:18:17 - Jammu Links News
What is the risk reward ratio of investing in SAB Biotherapeutics Inc. Equity Warrant stockInvest smarter with advanced market data - Jammu Links News
What high frequency data says about SAB Biotherapeutics Inc.Momentum-Based Prediction for Quick Returns - Newser
What are SAB Biotherapeutics Inc. Equity Warrant company’s key revenue driversUnlock steady growth with low-risk stocks - Jammu Links News
What catalysts could drive SAB Biotherapeutics Inc. Equity Warrant stock higher in 2025Free Stock Index Interpretation - Jammu Links News
What are the latest earnings results for SAB Biotherapeutics Inc. Equity WarrantAchieve consistent profits with expert advice - Jammu Links News
How volatile is SAB Biotherapeutics Inc. stock compared to the marketTremendous gains - Jammu Links News
SAB Biotherapeutics Inc. Equity Warrant Stock Analysis and ForecastFree Stock Selection - Jammu Links News
When is SAB Biotherapeutics Inc. Equity Warrant stock expected to show significant growthBuild a diversified portfolio for risk management - Jammu Links News
What makes SAB Biotherapeutics Inc. stock price move sharplyExceptional return forecasts - Jammu Links News
What are SAB Biotherapeutics Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):